Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Avner Reshef

Showing results (41-50 of 64) with videos related to

Pageof 7
Sort By:
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 3, 2010
Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacksJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
Allergy and Asthma Proceedings|January 26, 2011
Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensityJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
The Lancet. Haematology|May 6, 2024
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension studyTimothy J Craig, Donald S Levy, Avner Reshef, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 9, 2025
Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema: APeX-S final resultsHenriette Farkas, Jonny G Peter, Marcin Stobiecki, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
The New England Journal of Medicine|May 31, 2024
Efficacy and Safety of Donidalorsen for Hereditary AngioedemaMarc A Riedl, Raffi Tachdjian, William R Lumry, et al.
Journal of Asthma and Allergy|March 2, 2026
Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1William R Lumry, Raffi Tachdjian, Timothy Craig, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|July 30, 2010
HAE international home therapy consensus documentHilary J Longhurst, Henriette Farkas, Timothy Craig, et al.
Clinical and Translational Allergy|June 23, 2021
Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S studyHenriette Farkas, Marcin Stobiecki, Jonny Peter, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2016
Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoLNieves Prior, Eduardo Remor, Elia Pérez-Fernández, et al.
Pageof 7

Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 3, 2010
Population pharmacokinetics of plasma-derived C1 esterase inhibitor concentrate used to treat acute hereditary angioedema attacksJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
Allergy and Asthma Proceedings|January 26, 2011
Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensityJonathan A Bernstein, Bruce Ritchie, Robyn J Levy, et al.
The Lancet. Haematology|May 6, 2024
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension studyTimothy J Craig, Donald S Levy, Avner Reshef, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 9, 2025
Long-term safety and efficacy of once-daily berotralstat in patients with hereditary angioedema: APeX-S final resultsHenriette Farkas, Jonny G Peter, Marcin Stobiecki, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
The New England Journal of Medicine|May 31, 2024
Efficacy and Safety of Donidalorsen for Hereditary AngioedemaMarc A Riedl, Raffi Tachdjian, William R Lumry, et al.
Journal of Asthma and Allergy|March 2, 2026
Donidalorsen for Long-Term Prophylaxis of Hereditary Angioedema Attacks: Results from the OASISplus Open-Label Extension Cohort at Year 1William R Lumry, Raffi Tachdjian, Timothy Craig, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology|July 30, 2010
HAE international home therapy consensus documentHilary J Longhurst, Henriette Farkas, Timothy Craig, et al.
Clinical and Translational Allergy|June 23, 2021
Long-term safety and effectiveness of berotralstat for hereditary angioedema: The open-label APeX-S studyHenriette Farkas, Marcin Stobiecki, Jonny Peter, et al.
The Journal of Allergy and Clinical Immunology. in Practice|March 13, 2016
Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoLNieves Prior, Eduardo Remor, Elia Pérez-Fernández, et al.
Pageof 7